Sirnaomics Ltd 02257
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 7.36
- Day Range
- HKD 7.30–7.66
- 52-Week Range
- HKD 5.64–59.00
- Bid/Ask
- HKD 7.43 / HKD 7.46
- Market Cap
- HKD 651.15 Mil
- Volume/Avg
- 4.2 Mil / 3.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 7.79%
Company Profile
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group’s operations and non-current assets are located at the United States of America and the mainland of the People’s Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 145
- Website
- https://www.sirnaomics.com
Comparables
Valuation
|
Metric
|
02257
|
02171
|
02181
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.20 | 1.88 | 10.18 |
Price/Sales | — | — | 16.03 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
02257
|
02171
|
02181
|
|---|---|---|---|
Quick Ratio | 3.44 | 9.49 | 0.69 |
Current Ratio | 4.51 | 9.55 | 1.08 |
Interest Coverage | −86.17 | −174.85 | −20.87 |
Quick Ratio
02257
02171
02181
Profitability
|
Metric
|
02257
|
02171
|
02181
|
|---|---|---|---|
Return on Assets (Normalized) | −60.85% | −28.70% | −20.43% |
Return on Equity (Normalized) | −108.56% | −35.29% | −79.65% |
Return on Invested Capital (Normalized) | −94.28% | −35.38% | −38.37% |
Return on Assets
02257
02171
02181
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bhlztgssj | Ynsmz | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tbpxytl | Zlwydm | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pyvcypwb | Ppgnf | $105.3 Bil | |
MRNA
| Moderna Inc | Xyzqbddc | Ggwv | $47.0 Bil | |
ARGX
| argenx SE ADR | Xdmzlhmzs | Nxpwg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fwmpvnjt | Zcsb | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dcqjkjjss | Sxrcj | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ckfprlxq | Yjjwbl | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tqyyjpbk | Qjssrdf | $12.7 Bil | |
INCY
| Incyte Corp | Ltlkgvjv | Bjzpsl | $12.0 Bil |